THMA CPE Circle 2026: Pharma Exec Networking Focus
The THMA CPE Circle 2026 offers pharmaceutical executives a valuable opportunity to network with Chief Physician Executives, focusing on physician sponsorship for formulary adoption. The spring event is in Fort Lauderdale, FL, in May, and the fall event is in Scottsdale, AZ, in October.
Key Takeaways
- THMA CPE Circle 2026 offers pharmaceutical executives a valuable opportunity to network with Chief Physician Executives.
- The spring event will be held May 11-13, 2026, in Fort Lauderdale, FL, and the fall event will take place October 26-28, 2026, in Scottsdale, AZ.
- A key focus is on fostering physician sponsorship to support formulary adoption and the inclusion of therapies in clinical pathways.
- Note that THMA CPE Circle 2026 is a networking event; no specific drug data or trial results will be presented.
The THMA CPE Circle 2026 will host two sessions, one in Fort Lauderdale, FL, in May and another in Scottsdale, AZ, in October. This executive forum is designed to connect pharmaceutical executives with Chief Physician Executives (CPEs) from independent health systems, facilitating discussions around formulary adoption and clinical pathway inclusion.
The THMA CPE Circle events are designed to foster relationships between industry leaders and Chief Physician Executives (CPEs) who influence clinical and purchasing decisions within their health systems. By maintaining a 1:1 health system-to-industry ratio and offering continuing education accreditation, the forum aims to provide a valuable and balanced environment for networking and knowledge exchange.
While specific presentations and abstracts are not yet available, the THMA CPE Circle 2026 is expected to cover a range of topics relevant to healthcare leadership. These may include AI governance, digital transformation, clinical ROI frameworks, policy changes affecting Medicaid and value-based care, systems thinking for organizational change, real-world evidence, precision medicine, managed care trends, ambulatory strategy, and workforce optimization. Note that agendas are not finalized as of April 22, 2026.
The THMA CPE Circle 2026 targets CEOs, Chief Growth Officers, and strategic product leaders from healthcare technology, pharma, and services companies. It is particularly relevant for industry leaders focused on clinical AI, care delivery technology, and workforce solutions, as well as pharma commercial, medical affairs, and strategic teams focused on formulary success. For pharmaceutical companies, the THMA CPE Circle offers a unique opportunity to engage with physician executives who play a key role in formulary decisions and clinical pathway development.
The THMA CPE Circle is best suited for therapeutic areas where physician governance significantly impacts health system decisions. The focus is on building physician sponsorship to drive formulary adoption or the inclusion of specific therapies in clinical protocols. These events are executive networking conferences, and not designed for the presentation of trial data.
As the event dates approach, keep an eye out for potential agenda updates and speaker announcements. Monitor industry publications and the THMA website for any late-breaking news or additional details about the sessions.
Frequently Asked Questions
-
What is the THMA CPE Circle?
It is an executive forum designed to connect pharmaceutical executives with Chief Physician Executives (CPEs) from independent health systems.
-
When and where are the THMA CPE Circle 2026 events?
The spring event is May 11-13, 2026, in Fort Lauderdale, FL, and the fall event is October 26-28, 2026, in Scottsdale, AZ.
-
Who should attend?
CEOs, Chief Growth Officers, and strategic product leaders from healthcare technology, pharma, and services companies.
-
What is the focus of the THMA CPE Circle?
The focus is on fostering physician sponsorship to support formulary adoption and the inclusion of therapies in clinical pathways.
-
Will there be presentations of clinical trial data?
No, the THMA CPE Circle is a networking event, and no specific drug data or trial results will be presented.
